Investors

Press Releases

Press Releases

Oct 09, 2020
Data to be presented at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) Results support clinical development of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS) and other IL-1R/TLR-driven autoimmune and inflammatory diseases , with Phase 1 trial on track for
Jun 11, 2020
Data to be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II Cambridge, Mass. (June 11, 2020) – Kymera Therapeutics, Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients,
Displaying 1 - 10 of 12